Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer. The TPST news feed on Stock Titan aggregates company announcements, financial updates, and regulatory milestones that shape the outlook for this oncology-focused biotech.
Investors following TPST news can expect frequent updates on the progress of Tempest’s key programs, including amezalpat (TPST-1120), a selective PPAR⍺ antagonist in development for hepatocellular carcinoma, and TPST-1495, a dual EP2/4 prostaglandin receptor antagonist being advanced for familial adenomatous polyposis. News items often highlight clinical data presentations, regulatory designations from agencies such as the FDA, EMA and China’s NMPA, and clearances or agreements for pivotal or registration-directed trials.
The company also regularly reports quarterly financial results and business updates, detailing research and development spending, cash position, and its ongoing evaluation of strategic alternatives. Capital markets activity, such as registered direct offerings of common stock, private placements of warrants, and shelf registration usage, is disclosed through press releases and corresponding SEC filings and is reflected in the TPST news stream.
In addition, Tempest issues news on strategic transactions, including its agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates, which is intended to expand and diversify its clinical-stage pipeline. For market participants tracking TPST, this news page provides a centralized view of clinical, regulatory, financial, and transactional developments. Users interested in Tempest’s evolving oncology pipeline and corporate strategy can review past announcements and monitor new releases as they are published.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of an abstract for the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The abstract focuses on TPST-1495, an EP2/EP4 prostaglandin receptor dual antagonist.
Presentation Details:
- Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
- Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
- Session Date and Time: June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
- Abstract Number: 3107
The abstract will be released on May 25, 2023, at 5:00 p.m. ET on the ASCO website.
Tempest Therapeutics, Inc. (Nasdaq: TPST) recently presented new data from its TPST-1120 and TREX1 programs at the 2023 American Association for Cancer Research Annual Meeting. The findings from TPST-1120, an oral PPAR⍺ antagonist, highlighted biomarker changes linked to drug exposure and response levels in patients undergoing treatment in a Phase 1 trial. Additionally, the TREX1 inhibitor program showcased novel human TREX1 enzyme structures, paving the way for potent inhibitors targeting the STING pathway. The company aims to advance TPST-1120 through multiple oncology indications and initiate human trials for the TREX1 inhibitors. Initial results from ongoing trials are expected soon, indicating promising possibilities for future cancer therapies.
Tempest Therapeutics, Inc. (TPST) reported significant clinical progress in 2022, highlighted by the completion of a Phase 1 study for TPST-1120, indicating a 30% objective response rate in patients unresponsive to traditional therapies. The randomization study in collaboration with Roche for first-line hepatocellular carcinoma (HCC) patients is fully enrolled, with data expected in mid-2023. Financially, Tempest saw a decline in cash reserves to $31.2 million and a net loss of $35.7 million for the year. However, the company anticipates adequate funding through Q2 2024, with ongoing developments in TPST-1495 and a promising TREX1 inhibitor program.